Brown AS, Meyer U. Maternal immune activation and neuropsychiatric illness: a translational research perspective. Am J Psychiatry. 2018;175:1073–83.
Meyer U. Neurodevelopmental resilience and susceptibility to maternal immune activation. Trends Neurosci. 2019;42:793–806.
Gumusoglu SB, Stevens HE. Maternal inflammation and neurodevelopmental programming: a review of preclinical outcomes and implications for translational psychiatry. Biol Psychiatry. 2019;85:107–21.
Vasistha NA, Sawa A. Prenatal immune stress: its impact on brain development and neuropsychiatric disorders. Annu Rev Neurosci. 2025;2025. https://doi.org/10.1146/annurev-neuro-112723-024048.
Jones KL, Croen LA, Yoshida CK, Heuer L, Hansen R, Zerbo O, et al. Autism with intellectual disability is associated with increased levels of maternal cytokines and chemokines during gestation. Mol Psychiatry. 2017;22:273–9.
Mahic M, Che X, Susser E, Levin B, Reichborn-Kjennerud T, Magnus P, et al. Epidemiological and serological investigation into the role of gestational maternal influenza virus infection and autism spectrum disorders. mSphere. 2017;2:e00159–17.
Hornig M, Bresnahan MA, Che X, Schultz AF, Ukaigwe JE, Eddy ML, et al. Prenatal fever and autism risk. Mol Psychiatry. 2018;23:759–66.
Fajardo-Martinez V, Ferreira F, Fuller T, Cambou MC, Kerin T, Paiola S, et al. Neurodevelopmental delay in children exposed to maternal SARS-CoV-2 in-utero. Sci Rep. 2024;14:11851.
Mueller FS, Scarborough J, Schalbetter SM, Richetto J, Kim E, Couch A, et al. Behavioral, neuroanatomical, and molecular correlates of resilience and susceptibility to maternal immune activation. Mol Psychiatry. 2021;26:396–410.
Lorusso JM, Woods RM, McEwan F, Glazier JD, Neill JC, Harte M, et al. Clustering of cognitive phenotypes identifies susceptible and resilient offspring in a rat model of maternal immune activation and early-life stress. Brain Behav Immun. 2022;25:100514.
Herrero F, Mueller FS, Gruchot J, Küry P, Weber-Stadlbauer U, Meyer U. Susceptibility and resilience to maternal immune activation are associated with differential expression of endogenous retroviral elements. Brain Behav Immun. 2023;107:201–14.
Schaer R, Mueller FS, Notter T, Weber-Stadlbauer U, Meyer U. Intrauterine position effects in a mouse model of maternal immune activation. Brain Behav Immun. 2024;120:391–402.
Weber-Stadlbauer U, Meyer U. Challenges and opportunities of a-priori and a-posteriori variability in maternal immune activation models. Curr Opin. Behav Sci. 2019;28:119–28.
Schaer R, Wenger N, Herrero F, Notter T, Meyer U. Ontogeny and plasticity of resilience and susceptibility in a mouse model of maternal immune activation. Brain Behav Immun. 2025;129:666–80.
Biederman J, Monuteaux MC, Mick E, Spencer T, Wilens TE, Silva JM, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med. 2006;36:167–79.
Franke B, Michelini G, Asherson P, Banaschewski T, Bilbow A, Buitelaar JK, et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur Neuropsychopharmacol. 2018;28:1059–88.
Faraone SV, Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128:789–818.
Faraone SV, Bellgrove MA, Brikell I, Cortese S, Hartman CA, Hollis C, et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primer. 2024;10:11.
Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163:716–23.
Antshel KM, Zhang-James Y, Wagner KE, Ledesma A, Faraone SV. An update on the comorbidity of ADHD and ASD: a focus on clinical management. Expert Rev Neurother. 2016;16:279–93.
Rong Y, Yang C-J, Jin Y, Wang Y. Prevalence of attention-deficit/hyperactivity disorder in individuals with autism spectrum disorder: a meta-analysis. Res Autism Spectr Disord. 2021;83:101759.
Bamford J, Qurashi I, Axiaq A, Marwaha S, Husain N. Comorbid ADHD and schizophrenia and the use of psychostimulants: a scoping review protocol. BMJ Open. 2024;14:e090290.
Cheng N, Bryce S, Takagi M, Pert A, Rattray A, Fisher E, et al. The prevalence of attention deficit hyperactivity disorder in psychotic disorders: systematic review and meta-analysis. Schizophr Bull. 2025; 51:1514–28.
Luykx JJ, Corbeil O, Kärkkäinen O, Tanskanen A, Mittendorfer-Rutz E, Tiihonen J, et al. Long term safety of ADHD medication in patients with schizophrenia spectrum disorders. Mol Psychiatry. 2025;30:4859–67.
Cheung C, Yu K, Fung G, Leung M, Wong C, Li Q, et al. Autistic disorders and schizophrenia: related or remote? An anatomical likelihood estimation. PloS One. 2010;5:e12233.
Meyer U, Feldon J, Dammann O. Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr Res. 2011;69:26R–33R.
Moreno-De-Luca A, Myers SM, Challman TD, Moreno-De-Luca D, Evans DW, Ledbetter DH. Developmental brain dysfunction: revival and expansion of old concepts based on new genetic evidence. Lancet Neurol. 2013;12:406–14.
Gandal MJ, Haney JR, Parikshak NN, Leppa V, Ramaswami G, Hartl C, et al. Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. Focus. 2019;17:66–72.
Owen MJ, O’Donovan MC. Schizophrenia and the neurodevelopmental continuum:evidence from genomics. World Psychiatry. 2017;16:227–35.
Instanes JT, Halmøy A, Engeland A, Haavik J, Furu K, Klungsøyr K. Attention-deficit/hyperactivity disorder in offspring of mothers with inflammatory and immune system diseases. Biol Psychiatry. 2017;81:452–9.
Gustavson K, Ask H, Ystrom E, Stoltenberg C, Lipkin WI, Surén P, et al. Maternal fever during pregnancy and offspring attention deficit hyperactivity disorder. Sci Rep. 2019;9:9519.
Cowell WJ, Bellinger DC, Wright RO, Wright RJ. Antenatal active maternal asthma and other atopic disorders is associated with ADHD behaviors among school-aged children. Brain Behav Immun. 2019;80:871–8.
Nielsen TC, Nassar N, Shand AW, Jones HF, Han VX, Patel S, et al. Association between cumulative maternal exposures related to inflammation and child attention-deficit/hyperactivity disorder: a cohort study. Paediatr Perinat Epidemiol. 2024;38:241–50.
Borbye-Lorenzen N, Holmgaard S, Ottosson F, Nudel R, Appadurai V, Laursen TM, et al. High level of immunoglobulin G targeting mycoplasma or cytomegalovirus in the newborn increases risk of ADHD. Brain Behav Immun. 2025;123:99–107.
Walle KM, Gustavson K, Mjaaland S, Askeland RB, Magnus P, Susser E, et al. Maternal immune-mediated conditions and ADHD risk in offspring. BMC Med. 2025;23:348.
Wang T, Mohammadzadeh P, Jepsen JRM, Thorsen J, Rosenberg JB, Koldbæk Lemvigh C, et al. Maternal inflammatory proteins in pregnancy and neurodevelopmental disorders at age 10 years. JAMA Psychiatry. 2025;82:514–25.
Ginsberg Y, D’Onofrio BM, Rickert ME, Class QA, Rosenqvist MA, Almqvist C, et al. Maternal infection requiring hospitalization during pregnancy and attention-deficit hyperactivity disorder in offspring: a quasi-experimental family-based study. J Child Psychol Psychiatry. 2019;60:160–8.
Chudal R, Brown AS, Gyllenberg D, Hinkka-Yli-Salomäki S, Sucksdorff M, Surcel H-M, et al. Maternal serum C-reactive protein (CRP) and offspring attention deficit hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry. 2020;29:239–47.
Jallow J, Halt A-H, Öhman H, Hurtig T. Prenatal inflammation does not increase the risk for symptoms of attention deficit hyperactivity disorder (ADHD) in offspring. Eur Child Adolesc Psychiatry. 2021;30:1825–8.
Ellul P, Wallez S, Acquaviva E, Rosenzwajg M, Klatzmann D, Delorme R, et al. Children with a history of both maternal immune activation and prematurity are not at increased risk of ADHD symptoms. Eur Child Adolesc Psychiatry. 2024;33:2001–4.
Kanarik M, Grimm O, Mota NR, Reif A, Harro J. ADHD co-morbidities: A review of implication of gene × environment effects with dopamine-related genes. Neurosci Biobehav Rev. 2022;139:104757.
Gershon J. A meta-analytic review of gender differences in ADHD. J Atten Disord. 2002;5:143–54.
Scheres A, Milham MP, Knutson B, Castellanos FX. Ventral striatal hyporesponsiveness during reward anticipation in attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61:720–4.
Scheres A, Tontsch C, Thoeny AL, Kaczkurkin A. Temporal reward discounting in attention-deficit/hyperactivity disorder: the contribution of symptom domains, reward magnitude, and session length. Biol Psychiatry. 2010;67:641–8.
Volkow ND, Wang G-J, Newcorn JH, Kollins SH, Wigal TL, Telang F, et al. Motivation deficit in ADHD is associated with dysfunction of the dopamine reward pathway. Mol Psychiatry. 2011;16:1147–54.
Wilbertz G, van Elst LT, Delgado MR, Maier S, Feige B, Philipsen A, et al. Orbitofrontal reward sensitivity and impulsivity in adult attention deficit hyperactivity disorder. NeuroImage. 2012;60:353–61.
Hasson R, Fine JG. Gender differences among children with ADHD on continuous performance tests: a meta-analytic review. J Atten Disord. 2012;16:190–8.
Patros CHG, Alderson RM, Kasper LJ, Tarle SJ, Lea SE, Hudec KL. Choice-impulsivity in children and adolescents with attention-deficit/hyperactivity disorder (ADHD): A meta-analytic review. Clin Psychol Rev. 2016;43:162–74.
Marx I, Hacker T, Yu X, Cortese S, Sonuga-Barke E. ADHD and the choice of small immediate over larger delayed rewards: a comparative meta-analysis of performance on simple choice-delay and temporal discounting paradigms. J Atten Disord. 2021;25:171–87.
Kirley A, Hawi Z, Daly G, McCarron M, Mullins C, Millar N, et al. Dopaminergic system genes in ADHD: toward a biological hypothesis. Neuropsychopharmacology. 2002;27:607–19.
Spencer TJ, Biederman J, Madras BK, Faraone SV, Dougherty DD, Bonab AA, et al. In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol Psychiatry. 2005;57:1293–1300.
Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2011;69:e145–157.
Vanicek T, Spies M, Rami-Mark C, Savli M, Höflich A, Kranz GS, et al. The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography. JAMA Psychiatry. 2014;71:1340–9.
Ulke C, Rullmann M, Huang J, Luthardt J, Becker G-A, Patt M, et al. Adult attention-deficit/hyperactivity disorder is associated with reduced norepinephrine transporter availability in right attention networks: a (S,S)-O-[11C]methylreboxetine positron emission tomography study. Transl Psychiatry. 2019;9:301.
MacDonald HJ, Kleppe R, Szigetvari PD, Haavik J. The dopamine hypothesis for ADHD: An evaluation of evidence accumulated from human studies and animal models. Front Psychiatry. 2024;15:1492126.
Brown KA, Samuel S, Patel DR. Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitioners. Transl Pediatr. 2018;7:36–47.
Mechler K, Banaschewski T, Hohmann S, Häge A. Evidence-based pharmacological treatment options for ADHD in children and adolescents. Pharmacol Ther. 2022;230:107940.
Mueller FS, Polesel M, Richetto J, Meyer U, Weber-Stadlbauer U. Mouse models of maternal immune activation: mind your caging system!. Brain Behav Immun. 2018;73:643–60.
Mueller FS, Richetto J, Hayes LN, Zambon A, Pollak DD, Sawa A, et al. Influence of poly(I:C) variability on thermoregulation, immune responses and pregnancy outcomes in mouse models of maternal immune activation. Brain Behav Immun. 2019;80:406–18.
Tillmann KE, Schaer R, Mueller FS, Mueller K, Voelkl B, Weber-Stadlbauer U, et al. Differential effects of purified low molecular weight Poly(I:C) in the maternal immune activation model depend on the laboratory environment. Transl Psychiatry. 2024;14:300.
Kentner AC, Bilbo SD, Brown AS, Hsiao EY, McAllister AK, Meyer U, et al. Maternal immune activation: reporting guidelines to improve the rigor, reproducibility, and transparency of the model. Neuropsychopharmacology. 2019;44:245–58.
Belzung C, Griebel G. Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav Brain Res. 2001;125:141–9.
Scarborough J, Mueller F, Arban R, Dorner-Ciossek C, Weber-Stadlbauer U, Rosenbrock H, et al. Preclinical validation of the micropipette-guided drug administration (MDA) method in the maternal immune activation model of neurodevelopmental disorders. Brain Behav Immun. 2020;88:461–70.
Schalbetter SM, Mueller FS, Scarborough J, Richetto J, Weber-Stadlbauer U, Meyer U, et al. Oral application of clozapine-N-oxide using the micropipette-guided drug administration (MDA) method in mouse DREADD systems. Lab Anim. 2021;50:69–75.
Krzyzaniak O, Steiner S, Nilsson FAM, Dietrich M, Kämpfen L, Johansen P, et al. Applicability of the micropipette-guided drug administration (MDA) method for assessing reward-related behaviors in mice. Physiol Behav. 2025;299:114967.
Zimmermann A-M, Jene T, Wolf M, Görlich A, Gurniak CB, Sassoè-Pognetto M, et al. Attention-deficit/hyperactivity disorder-like phenotype in a mouse model with impaired actin dynamics. Biol Psychiatry. 2015;78:95–106.
Bouchatta O, Manouze H, Bouali-Benazzouz R, Kerekes N, Ba-M’hamed S, Fossat P, et al. Neonatal 6-OHDA lesion model in mouse induces Attention-Deficit/ Hyperactivity Disorder (ADHD)-like behaviour. Sci Rep. 2018;8:15349.
Hori T, Ikuta S, Hattori S, Takao K, Miyakawa T, Koike C. Mice with mutations in Trpm1, a gene in the locus of 15q13.3 microdeletion syndrome, display pronounced hyperactivity and decreased anxiety-like behavior. Mol Brain. 2021;14:61.
Kiryk A, Janusz A, Zglinicki B, Turkes E, Knapska E, Konopka W, et al. IntelliCage as a tool for measuring mouse behavior – 20 years perspective. Behav Brain Res. 2020;388:112620.
Iman IN, Yusof NAM, Talib UN, Ahmad NAZ, Norazit A, Kumar J, et al. The IntelliCage System: a review of its utility as a novel behavioral platform for a rodent model of substance use disorder. Front Behav Neurosci. 2021;15:683780.
Nigri M, Bramati G, Steiner AC, Wolfer DP. Appetitively motivated tasks in the IntelliCage reveal a higher motivational cost of spatial learning in male than female mice. Front Behav Neurosci. 2024;18:1270159.
Lipp H-P, Krackow S, Turkes E, Benner S, Endo T, Russig H. IntelliCage: the development and perspectives of a mouse- and user-friendly automated behavioral test system. Front Behav Neurosci. 2024;17:1270538.
Primo MJ, Fonseca-Rodrigues D, Almeida A, Teixeira PM, Pinto-Ribeiro F. Sucrose preference test: a systematic review of protocols for the assessment of anhedonia in rodents. Eur Neuropsychopharmacology. 2023;77:80–92.
Robbins TW, Everitt BJ. Neurobehavioural mechanisms of reward and motivation. Curr Opin Neurobiol. 1996;6:228–36.
Wrenn CC, French E, Baker D, McCallian R, Kirk R, Reilly MP, et al. Effects of clonidine on progressive ratio schedule performance in Fmr1 knockout mice. Psychopharmacology. 2021;238:1133–40.
Delaney J, Nathani S, Tan V, Chavez C, Orr A, Paek J, et al. Enhanced cognitive flexibility and phasic striatal dopamine dynamics in a mouse model of low striatal tonic dopamine. Neuropsychopharmacology. 2024;49:1600–8.
Isles AR, Humby T, Wilkinson LS. Measuring impulsivity in mice using a novel operant delayed reinforcement task: effects of behavioural manipulations and d-amphetamine. Psychopharmacology. 2003;170:376–82.
Johansen EB, Sagvolden T, Kvande G. Effects of delayed reinforcers on the behavior of an animal model of attention-deficit/hyperactivity disorder (ADHD). Behav Brain Res. 2005;162:47–61.
Hand DJ, Fox AT, Reilly MP. Response acquisition with delayed reinforcement in a rodent model of attention-deficit/hyperactivity disorder (ADHD). Behav Brain Res. 2006;175:337–42.
Swerdlow NR, Weber M, Qu Y, Light GA, Braff DL. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology. 2008;199:331–88.
Notter T, Schalbetter SM, Clifton NE, Mattei D, Richetto J, Thomas K, et al. Neuronal activity increases translocator protein (TSPO) levels. Mol Psychiatry. 2021;26:2025–37.
Schalbetter SM, von Arx AS, Cruz-Ochoa N, Dawson K, Ivanov A, Mueller FS, et al. Adolescence is a sensitive period for prefrontal microglia to act on cognitive development. Sci Adv. 2022;8:eabi6672.
Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1397–409.
Roessner V, Sagvolden T, Dasbanerjee T, Middleton FA, Faraone SV, Walaas SI, et al. Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type. Neuroscience. 2010;167:1183–91.
Miller EM, Pomerleau F, Huettl P, Russell VA, Gerhardt GA, Glaser PEA. The spontaneously hypertensive and Wistar Kyoto rat models of ADHD exhibit sub-regional differences in dopamine release and uptake in the striatum and nucleus accumbens. Neuropharmacology. 2012;63:1327–34.
Somkuwar SS, Kantak KM, Dwoskin LP. Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder. J Neurosci Methods. 2015;252:55–63.
Kantak KM. Rodent models of attention-deficit hyperactivity disorder: An updated framework for model validation and therapeutic drug discovery. Pharmacol Biochem Behav. 2022;216:173378.
Bacopoulos NG, Bhatnagar RK. Correlation between tyrosine hydroxylase activity and catecholamine concentration or turnover in brain regions. J Neurochem. 1977;29:639–43.
Cimarusti DL, Saito K, Vaughn JE, Barber R, Roberts E, Thomas PE. Immunocytochemical localization of dopamine-beta-hydroxylase in rat locus coeruleus and hypothalamus. Brain Res. 1979;162:55–67.
Aguilar-Valles A, Rodrigue B, Matta-Camacho E. Maternal immune activation and the development of dopaminergic neurotransmission of the offspring: relevance for schizophrenia and other psychoses. Front Psychiatry. 2020;11:852.
Meyer U, Nyffeler M, Schwendener S, Knuesel I, Yee BK, Feldon J. Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology. 2008;33:441–56.
Vuillermot S, Weber L, Feldon J, Meyer U. A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J Neurosci. 2010;30:1270–87.
Schroeter S, Apparsundaram S, Wiley RG, Miner LH, Sesack SR, Blakely RD. Immunolocalization of the cocaine- and antidepressant-sensitive l-norepinephrine transporter. J Comp Neurol. 2000;420:211–32.
Miner LH, Schroeter S, Blakely RD, Sesack SR. Ultrastructural localization of the norepinephrine transporter in superficial and deep layers of the rat prelimbic prefrontal cortex and its spatial relationship to probable dopamine terminals. J Comp Neurol. 2003;466:478–94.
Ranjbar-Slamloo Y, Fazlali Z. Dopamine and noradrenaline in the brain; overlapping or dissociate functions? Front Mol Neurosci. 2019;12:334.
Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36:159–65.
Di Lorenzo R, Balducci J, Poppi C, Arcolin E, Cutino A, Ferri P, et al. Children and adolescents with ADHD followed up to adulthood: a systematic review of long-term outcomes. Acta Neuropsychiatr. 2021;33:283–98.
Meyer U, Feldon J, Schedlowski M, Yee BK. Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev. 2005;29:913–47.
Meyer U, Nyffeler M, Yee BK, Knuesel I, Feldon J. Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun. 2008;22:469–86.
Meyer U, Feldon J. Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog Neurobiol. 2010;90:285–326.
Hawk LW, Yartz AR, Pelham WE, Lock TM. The effects of methylphenidate on prepulse inhibition during attended and ignored prestimuli among boys with attention-deficit hyperactivity disorder. Psychopharmacology. 2003;165:118–27.
Feifel D, Minassian A, Perry W. Prepulse inhibition of startle in adults with ADHD. J Psychiatr Res. 2009;43:484–9.
Conzelmann A, Pauli P, Mucha RF, Jacob CP, Gerdes ABM, Romanos J, et al. Early attentional deficits in an attention-to-prepulse paradigm in ADHD adults. J Abnorm Psychol. 2010;119:594–603.
Sommer J, le, Low A-M, Jepsen JRM, Fagerlund B, Vangkilde S, Habekost T, et al. Effects of methylphenidate on sensory and sensorimotor gating of initially psychostimulant-naïve adult ADHD patients. Eur Neuropsychopharmacology. 2021;46:83–92.
Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology. 2001;156:234–58.
Richetto J, Massart R, Weber-Stadlbauer U, Szyf M, Riva MA, Meyer U. Genome-wide DNA methylation changes in a mouse model of infection-mediated neurodevelopmental disorders. Biol Psychiatry. 2017;81:265–76.
Richetto J, Calabrese F, Riva MA, Meyer U. Prenatal immune activation induces maturation-dependent alterations in the prefrontal GABAergic transcriptome. Schizophr Bull. 2014;40:351–61.
Bubser M, Schmidt WJ. 6-Hydroxydopamine lesion of the rat prefrontal cortex increases locomotor activity, impairs acquisition of delayed alternation tasks, but does not affect uninterrupted tasks in the radial maze. Behav Brain Res. 1990;37:157–68.
Bari A, Robbins TW. Inhibition and impulsivity: behavioral and neural basis of response control. Prog Neurobiol. 2013;108:44–79.
Novick AM, Forster GL, Hassell JE, Davies DR, Scholl JL, Renner KJ, et al. Increased dopamine transporter function as a mechanism for dopamine hypoactivity in the adult infralimbic medial prefrontal cortex following adolescent social stress. Neuropharmacology. 2015;97:194–200.
Moreno M, Azocar V, Vergés A, Fuentealba JA. High impulsive choice is accompanied by an increase in dopamine release in rat dorsolateral striatum. Behav Brain Res. 2021;405:113199.
Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Soc Neurosci. 1998;18:5901–7.
Dresel S, Krause J, Krause KH, LaFougere C, Brinkbäumer K, Kung HF, et al. Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. Eur J Nucl Med. 2000;27:1518–24.
Volkow ND, Wang G-J, Newcorn J, Fowler JS, Telang F, Solanto MV, et al. Brain dopamine transporter levels in treatment and drug naïve adults with ADHD. NeuroImage. 2007;34:1182–90.
Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiatry. 2012;169:264–72.
Wang G-J, Volkow ND, Wigal T, Kollins SH, Newcorn JH, Telang F, et al. Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder. PLoS ONE. 2013;8:e63023.
Sagvolden T, Russell VA, Aase H, Johansen EB, Farshbaf M. Rodent models of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57:1239–47.
Russell VA. Neurobiology of animal models of attention-deficit hyperactivity disorder. J Neurosci Methods. 2007;161:185–98.
Liu D, Xie Z, Gu P, Li X, Zhang Y, Wang X, et al. Cry1Δ11 mutation induces ADHD-like symptoms through hyperactive dopamine D1 receptor signaling. JCI Insight. 2023;8:e170434.
Ohno Y, Okano M, Masui A, Imaki J, Egawa M, Yoshihara C, et al. Region-specific elevation of D₁ receptor-mediated neurotransmission in the nucleus accumbens of SHR, a rat model of attention deficit/hyperactivity disorder. Neuropharmacology. 2012;63:547–54.
Jogamoto T, Utsunomiya R, Sato A, Kihara N, Choudhury ME, Miyanishi K, et al. Lister hooded rats as a novel animal model of attention-deficit/hyperactivity disorder. Neurochem Int. 2020;141:104857.
Monfil T, Vázquez Roque RA, Camacho-Abrego I, Tendilla-Beltran H, Iannitti T, Meneses-Morales I, et al. Hyper-response to novelty increases c-Fos expression in the hippocampus and prefrontal cortex in a rat model of schizophrenia. Neurochem Res. 2018;43:441–8.
Sethi A, Voon V, Critchley HD, Cercignani M, Harrison NA. A neurocomputational account of reward and novelty processing and effects of psychostimulants in attention deficit hyperactivity disorder. Brain J Neurol. 2018;141:1545–57.
Arnsten AFT, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav. 2011;99:211–6.
Meyer U, Feldon J, Schedlowski M, Yee BK. Immunological stress at the maternal-foetal interface: a link between neurodevelopment and adult psychopathology. Brain Behav Immun. 2006;20:378–88.
Canetta S, Bolkan S, Padilla-Coreano N, Song LJ, Sahn R, Harrison NL, et al. Maternal immune activation leads to selective functional deficits in offspring parvalbumin interneurons. Mol Psychiatry. 2016;21:956–68.
Deane AR, Jing Y, Shoorangiz R, Liu P, Ward RD. Cognitive and arginine metabolic correlates of temporal dysfunction in the MIA rat model of schizophrenia risk. Behav Neurosci. 2023;137:67–77.
Maroon M, Haddad F, Doornaert E, Allman B, Schmid S. Investigating gene-environment interaction on attention in a double-hit model for Autism Spectrum Disorder. PLoS ONE. 2024;19:e0299380.
Hubbard JA, Chen S, Iosif AM, Ryan AM, Murai T, Hogrefe CE, et al. Maternal immune activation alters infant attentional processing in a nonhuman primate model. Brain Behav Immun. 2025;48:101075.
Zarchev M, Gigase FAJ, de Witte L, Cecil CAM, Hillegers MHJ, Ospina LH, et al. Maternal infection – but not inflammation – is associated with attention-deficit/hyperactivity disorder symptoms during childhood: a population-based cohort study. Brain Behav Immun. 2025;131:106134.
Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry. 2019;24:562–75.
